Skip to Main Content

Less than two months after the Food and Drug Administration approved the first-ever drug that uses a Nobel-winning technique to mute disease-causing genes, the pharmaceutical industry is already looking for a piece of the next one.

Within the last month, Eli Lilly, Alexion, and Janssen have all announced licensing and collaboration deals — each potentially worth billions — with companies developing treatments with the technique known as RNAi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.